Multiresistant Enterobacteriaceae: new threat of an old problem

References

• Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis.42(5), 657–668 (2006).
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother.50(4), 1257–1262 (2006).
   PubMed Web of Science ®Google Scholar
• Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am. J. Infect. Control34(5 Suppl. 1), S20–S28 (2006).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol.14(9), 413–420 (2006).
   PubMed Web of Science ®Google Scholar
• Jacoby GA, Munoz-Price LS. The new β-lactamases. N. Engl. J. Med.352(4), 380–391 (2005).
   PubMed Web of Science ®Google Scholar
• Jacoby GA. Mechanisms of resistance to quinolones. Clin. Infect. Dis.41(Suppl. 2), S120–S126 (2005).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev.18(4), 657–686 (2005).
   PubMed Web of Science ®Google Scholar
• Gniadkowski M. Evolution of extended-spectrum β-lactamases by mutation. Clin. Microbiol. Infect.14(Suppl. 1), 11–32 (2008).
   PubMed Web of Science ®Google Scholar
• Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. Curr. Opin. Pharmacol.7(5), 459–469 (2007).
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis.8(3), 159–166 (2008).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother.59(2), 165–174 (2007).
   PubMed Web of Science ®Google Scholar
• Canton R, Coque TM. The CTX-M β-lactamase pandemic. Curr. Opin. Microbiol.9(5), 466–475 (2006).
   PubMed Web of Science ®Google Scholar
• Rossolini GM, D’Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum β-lactamases. Clin. Microbiol. Infect.14(Suppl. 1), 33–41 (2008).
   PubMed Web of Science ®Google Scholar
• Coque TM, Novais A, Carattoli A et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15. Emerg. Infect. Dis.14(2), 195–200 (2008).
   PubMed Web of Science ®Google Scholar
• Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J. Antimicrob. Chemother.61(2), 273–281 (2008).
   PubMed Web of Science ®Google Scholar
• Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J. Antimicrob. Chemother.56(1), 52–59 (2005).
   PubMed Web of Science ®Google Scholar
• Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum β-lactamases: importance of community isolates with blaCTX-M genes. Clin. Infect. Dis.38(12), 1736–1741 (2004).
   PubMed Web of Science ®Google Scholar
• Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J. Antimicrob. Chemother.54(4), 735–743 (2004).
   PubMed Web of Science ®Google Scholar
• Oteo J, Navarro C, Cercenado E et al. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J. Clin. Microbiol.44(7), 2359–2366 (2006).
   PubMed Web of Science ®Google Scholar
• Mugnaioli C, Luzzaro F, De Luca F et al. CTX-M-type extended-spectrum β-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob. Agents Chemother.50(8), 2700–2706 (2006).
   PubMed Web of Science ®Google Scholar
• Quinteros M, Radice M, Gardella N et al. Extended-spectrum β-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob. Agents Chemother.47(9), 2864–2867 (2003).
   PubMed Web of Science ®Google Scholar
• Mulvey MR, Bryce E, Boyd D et al. Ambler class A extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob. Agents Chemother.48(4), 1204–1214 (2004).
   PubMed Web of Science ®Google Scholar
• Pitout JD, Church DL, Gregson DB et al. Molecular epidemiology of CTX-M-producing Escherichia coli in the calgary health region: emergence of CTX-M-15-producing isolates. Antimicrob. Agents Chemother.51(4), 1281–1286 (2007).
   PubMedGoogle Scholar
• Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother.51(6), 1987–1994 (2007).
   PubMed Web of Science ®Google Scholar
• Nicolas-Chanoine MH, Jarlier V. Extended-spectrum β -lactamases in long-term-care facilities. Clin. Microbiol. Infect.14(Suppl. 1), 111–116 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD. Extended-spectrum β-lactamases in ambulatory care: a clinical perspective. Clin. Microbiol. Infect.14(Suppl. 1), 104–110 (2008).
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Schwaber MJ, Navon-Venezia S et al. Influx of extended-spectrum β-lactamase-producing enterobacteriaceae into the hospital. Clin. Infect. Dis.42(7), 925–934 (2006).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Romero L et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Clin. Microbiol. Infect.14(2), 180–183 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis.43(11), 1407–1414 (2006).
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 18th Informational Supplement M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2008).
   Google Scholar
• Wiegand I, Geiss HK, Mack D, Sturenburg E, Seifert H. Detection of extended-spectrum β-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. J. Clin. Microbiol.45(4), 1167–1174 (2007).
   PubMed Web of Science ®Google Scholar
• Navon-Venezia S, Leavitt A, Ben-Ami R et al. Evaluation of an accelerated protocol for detection of extended-spectrum β-lactamase-producing Gram-negative bacilli from positive blood cultures. J. Clin. Microbiol.43(1), 439–441 (2005).
   PubMedGoogle Scholar
• Drieux L, Brossier F, Sougakoff W, Jarlier V. Phenotypic detection of extended-spectrum β-lactamase production in Enterobacteriaceae: review and bench guide. Clin. Microbiol. Infect.14(Suppl. 1), 90–103 (2008).
   PubMedGoogle Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev.20(3), 440–458 (2007).
   PubMed Web of Science ®Google Scholar
• Walther-Rasmussen J, Hoiby N. Class A carbapenemases. J. Antimicrob. Chemother.60(3), 470–482 (2007).
   PubMed Web of Science ®Google Scholar
• Bratu S, Brooks S, Burney S et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin. Infect. Dis.44(7), 972–975 (2007).
   PubMed Web of Science ®Google Scholar
• Chiang T, Mariano N, Urban C et al. Identification of carbapenem-resistant Klebsiella pneumoniae harboring KPC enzymes in New Jersey. Microb. Drug Resist.13(4), 235–239 (2007).
   PubMedGoogle Scholar
• Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin. Infect. Dis.43(3), E26–E28 (2006).
   PubMedGoogle Scholar
• Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States medical centers: report from the MYSTIC Program (1999–2005). Diagn. Microbiol. Infect. Dis.56(4), 367–372 (2006).
   PubMed Web of Science ®Google Scholar
• Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the β-lactamase blaKPC gene. Antimicrob. Agents Chemother.52(4), 1257–1263 (2008).
   PubMed Web of Science ®Google Scholar
• Endimiani A, Carias LL, Hujer AM et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob. Agents Chemother.52(7), 2680–2682 (2008).
   PubMed Web of Science ®Google Scholar
• Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol.2(5), 501–512 (2007).
   PubMed Web of Science ®Google Scholar
• Bratu S, Landman D, Haag R et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med.165(12), 1430–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Bradford PA, Bratu S, Urban C et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin. Infect. Dis.39(1), 55–60 (2004).
   PubMed Web of Science ®Google Scholar
• Bratu S, Mooty M, Nichani S et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother.49(7), 3018–3020 (2005).
   PubMed Web of Science ®Google Scholar
• Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob. Agents Chemother.51(8), 3026–3029 (2007).
   PubMed Web of Science ®Google Scholar
• Bratu S, Tolaney P, Karumudi U et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother.56(1), 128–132 (2005).
   PubMed Web of Science ®Google Scholar
• Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother.52(2), 570–573 (2008).
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000–2004). Microb. Drug Resist.12(4), 223–230 (2006).
   PubMed Web of Science ®Google Scholar
• Woodford N, Tierno PM Jr, Young K et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother.48(12), 4793–4799 (2004).
   PubMed Web of Science ®Google Scholar
• Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int. J. Antimicrob. Agents30(6), 525–529 (2007).
   PubMed Web of Science ®Google Scholar
• Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob. Agents Chemother.52(4), 1413–1418 (2008).
   PubMed Web of Science ®Google Scholar
• Urban C, Bradford PA, Tuckman M et al. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase β-lactamases associated with long-term care facilities. Clin. Infect. Dis.46(11), E127–E130 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson KF, Lonsway DR, Rasheed JK et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J. Clin. Microbiol.45(8), 2723–2725 (2007).
   PubMed Web of Science ®Google Scholar
• Tenover FC, Kalsi RK, Williams PP et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg. Infect. Dis.12(8), 1209–1213 (2006).
   PubMed Web of Science ®Google Scholar
• Marchiaro P, Ballerini V, Spalding T et al. A convenient microbiological assay employing cell-free extracts for the rapid characterization of Gram-negative carbapenemase producers. J. Antimicrob. Chemother.62(2), 336–344 (2008).
   PubMedGoogle Scholar
• Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev.18(2), 306–325 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta V. Metallo β lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin. Investig. Drugs17(2), 131–143 (2008).
   PubMed Web of Science ®Google Scholar
• Kassis-Chikhani N, Decre D, Gautier V et al. First outbreak of multidrug-resistant Klebsiella pneumoniae carrying blaVIM-1 and blaSHV-5 in a French University Hospital. J. Antimicrob. Chemother.57(1), 142–145 (2006).
   PubMedGoogle Scholar
• Vatopoulos A. High rates of metallo-β-lactamase-producing Klebsiella pneumoniae in Greece – a review of the current evidence. Euro Surveill.13(4), pii: 8023 (2008).
   Google Scholar
• Yong D, Choi YS, Roh KH et al. Increasing prevalence and diversity of metallo-β-lactamases in Pseudomonas spp., Acinetobacter spp., and Enterobacteriaceae from Korea. Antimicrob. Agents Chemother.50(5), 1884–1886 (2006).
   PubMed Web of Science ®Google Scholar
• Psichogiou M, Tassios PT, Avlamis A et al. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J. Antimicrob. Chemother.61(1), 59–63 (2008).
   PubMed Web of Science ®Google Scholar
• Tato M, Coque TM, Ruiz-Garbajosa P et al. Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-β-lactamase in Spain: toward endemicity? Clin. Infect. Dis.45(9), 1171–1178 (2007).
   PubMed Web of Science ®Google Scholar
• Cagnacci S, Gualco L, Roveta S et al. Bloodstream infections caused by multidrug-resistant Klebsiella pneumoniae producing the carbapenem-hydrolyzing VIM-1 metallo-β-lactamase: first Italian outbreak. J. Antimicrob. Chemother.61(2), 296–300 (2008).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of the metallo-β-lactamase gene blaIMP-4 among Gram-negative pathogens in a clinical setting in Australia. Clin. Infect. Dis.41(11), 1549–1556 (2005).
   PubMed Web of Science ®Google Scholar
• Souli M, Kontopidou FV, Papadomichelakis E, Galani I, Armaganidis A, Giamarellou H. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-β-lactamase in a Greek University Hospital. Clin. Infect. Dis.46(6), 847–854 (2008).
   PubMed Web of Science ®Google Scholar
• Cornaglia G, Akova M, Amicosante G et al. Metallo-β-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int. J. Antimicrob. Agents29(4), 380–388 (2007).
   PubMed Web of Science ®Google Scholar
• Petropoulou D, Tzanetou K, Syriopoulou VP, Daikos GL, Ganteris G, Malamou-Lada E. Evaluation of imipenem/imipenem+EDTA disk method for detection of metallo-β-lactamase-producing Klebsiella pneumoniae isolated from blood cultures. Microb. Drug Resist.12(1), 39–43 (2006).
   PubMedGoogle Scholar
• Mendes RE, Kiyota KA, Monteiro J et al. Rapid detection and identification of metallo-β-lactamase-encoding genes by multiplex real-time PCR assay and melt curve ana­lysis. J. Clin. Microbiol.45(2), 544–547 (2007).
   PubMed Web of Science ®Google Scholar
• Hanson ND. AmpC β-lactamases: what do we need to know for the future? J. Antimicrob. Chemother.52(1), 2–4 (2003).
   PubMed Web of Science ®Google Scholar
• Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother.46(1), 1–11 (2002).
   PubMed Web of Science ®Google Scholar
• Forward KR, Willey BM, Low DE et al. Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals. Diagn. Microbiol. Infect. Dis.41(1–2), 57–63 (2001).
   PubMed Web of Science ®Google Scholar
• Ding H, Yang Y, Lu Q et al. The prevalence of plasmid-mediated AmpC β-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children’s hospitals in China. Eur. J. Clin. Microbiol. Infect. Dis. PMID: 18449580 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Li Y, Li Q, Du Y et al. Prevalence of plasmid-mediated AmpC β-lactamases in a Chinese University Hospital from 2003 to 2005: first report of CMY-2-type AmpC β-lactamase resistance in China. J. Clin. Microbiol.46(4), 1317–1321 (2008).
   PubMed Web of Science ®Google Scholar
• Moland ES, Hanson ND, Black JA, Hossain A, Song W, Thomson KS. Prevalence of newer β-lactamases in Gram-negative clinical isolates collected in the United States from 2001 to 2002. J. Clin. Microbiol.44(9), 3318–3324 (2006).
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence of plasmidic AmpC type β-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). Int. J. Antimicrob. Agents28(6), 578–581 (2006).
   PubMedGoogle Scholar
• Woodford N, Reddy S, Fagan EJ et al. Wide geographic spread of diverse acquired AmpC β-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland. J. Antimicrob. Chemother.59(1), 102–105 (2007).
   PubMed Web of Science ®Google Scholar
• Alvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of conjugative plasmid-mediated AmpC β-lactamases in the United States. Antimicrob. Agents Chemother.48(2), 533–537 (2004).
   PubMed Web of Science ®Google Scholar
• Mulvey MR, Bryce E, Boyd DA et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob. Agents Chemother.49(1), 358–365 (2005).
   PubMed Web of Science ®Google Scholar
• Mocktar C, Govinden U, Sturm AW, Essack SY. CMY-20, a novel AmpC-type β-lactamase from South African clinical Escherichia coli isolates. Diagn. Microbiol. Infect. Dis.60(4), 405–408 (2008).
   PubMedGoogle Scholar
• Pai H, Kang CI, Byeon JH et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-β-lactamase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother.48(10), 3720–3728 (2004).
   PubMed Web of Science ®Google Scholar
• Varma JK, Marcus R, Stenzel SA et al. Highly resistant Salmonella Newport-MDRAmpC transmitted through the domestic US food supply: a FoodNet case–control study of sporadic Salmonella Newport infections, 2002–2003. J. Infect. Dis.194(2), 222–230 (2006).
   PubMed Web of Science ®Google Scholar
• Pitout JD, Gregson DB, Church DL, Laupland KB. Population-based laboratory surveillance for AmpC β-lactamase-producing Escherichia coli, Calgary. Emerg. Infect. Dis.13(3), 443–448 (2007).
   PubMed Web of Science ®Google Scholar
• Doi Y, Paterson DL. Detection of plasmid-mediated class C β-lactamases. Int. J. Infect. Dis.11(3), 191–197 (2007).
   PubMed Web of Science ®Google Scholar
• Coudron PE. Inhibitor-based methods for detection of plasmid-mediated AmpC β-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. J. Clin. Microbiol.43(8), 4163–4167 (2005).
   PubMed Web of Science ®Google Scholar
• Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol.40(6), 2153–2162 (2002).
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J. Antimicrob. Chemother.56(3), 463–469 (2005).
   PubMed Web of Science ®Google Scholar
• Cattoir V, Nordmann P, Silva-Sanchez J, Espinal P, Poirel L. ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli. Antimicrob. Agents Chemother. (2008).
   Google Scholar
• Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis.6(10), 629–640 (2006).
   PubMed Web of Science ®Google Scholar
• Cattoir V, Poirel L, Mazel D, Soussy CJ, Nordmann P. Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. Antimicrob. Agents Chemother.51(7), 2650–2651 (2007).
   PubMedGoogle Scholar
• Poirel L, Rodriguez-Martinez JM, Mammeri H, Liard A, Nordmann P. Origin of plasmid-mediated quinolone resistance determinant QnrA. Antimicrob. Agents Chemother.49(8), 3523–3525 (2005).
   PubMedGoogle Scholar
• Robicsek A, Strahilevitz J, Jacoby GA et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat. Med.12(1), 83–88 (2006).
   PubMed Web of Science ®Google Scholar
• Perichon B, Courvalin P, Galimand M. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob. Agents Chemother.51(7), 2464–2469 (2007).
   PubMed Web of Science ®Google Scholar
• Yamane K, Wachino J, Suzuki S et al. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob. Agents Chemother.51(9), 3354–3360 (2007).
   PubMed Web of Science ®Google Scholar
• Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J. Antimicrobial-resistant invasive Escherichia coli, Spain. Emerg. Infect. Dis.11(4), 546–553 (2005).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Rossi F, Baquero F et al.In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J. Antimicrob. Chemother.55(6), 965–973 (2005).
   PubMed Web of Science ®Google Scholar
• Ling TK, Xiong J, Yu Y, Lee CC, Ye H, Hawkey PM. Multicenter antimicrobial susceptibility survey of Gram-negative bacteria isolated from patients with community-acquired infections in the People’s Republic of China. Antimicrob. Agents Chemother.50(1), 374–378 (2006).
   PubMedGoogle Scholar
• Poirel L, Leviandier C, Nordmann P. Prevalence and genetic analysis of plasmid-mediated quinolone resistance determinants QnrA and QnrS in Enterobacteriaceae isolates from a French University Hospital. Antimicrob. Agents Chemother.50(12), 3992–3997 (2006).
   PubMed Web of Science ®Google Scholar
• Robicsek A, Sahm DF, Strahilevitz J, Jacoby GA, Hooper DC. Broader distribution of plasmid-mediated quinolone resistance in the United States. Antimicrob. Agents Chemother.49(7), 3001–3003 (2005).
   PubMed Web of Science ®Google Scholar
• Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC. Qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob. Agents Chemother.50(8), 2872–2874 (2006).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez JM, Pascual A, Garcia I, Martinez-Martinez L. Detection of the plasmid-mediated quinolone resistance determinant Qnr among clinical isolates of Klebsiella pneumoniae producing AmpC-type β-lactamase. J. Antimicrob. Chemother.52(4), 703–706 (2003).
   PubMedGoogle Scholar
• Wu JJ, Ko WC, Tsai SH, Yan JJ. Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital. Antimicrob. Agents Chemother.51(4), 1223–1227 (2007).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez JM, Poirel L, Pascual A, Nordmann P. Plasmid-mediated quinolone resistance in Australia. Microb. Drug Resist.12(2), 99–102 (2006).
   PubMedGoogle Scholar
• Pitout JD, Wei Y, Church DL, Gregson DB. Surveillance for plasmid-mediated quinolone resistance determinants in Enterobacteriaceae within the Calgary Health Region, Canada: the emergence of aac(6´)-Ib-cr. J. Antimicrob. Chemother.61(5), 999–1002 (2008).
   PubMedGoogle Scholar
• Poirel L, Pitout JD, Calvo L, Rodriguez-Martinez JM, Church D, Nordmann P. In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum β-lactamase. Antimicrob. Agents Chemother.50(4), 1525–1527 (2006).
   PubMed Web of Science ®Google Scholar
• Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem? Clin. Microbiol. Infect.14(4), 295–297 (2008).
   PubMedGoogle Scholar
• Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J. Antimicrob. Chemother.60(2), 394–397 (2007).
   PubMed Web of Science ®Google Scholar